Biotest
Rainer Schmeidl has a strong background in drug safety and pharmacovigilance. Rainer began their career at Hoechst in 1990 as a Corporate Drug Safety Project Manager. Rainer then moved to Hoechst-Marion-Roussel GmbH, where they held the position of Head of Drug Safety and Pharmacovigilance for HMR Germany. Rainer later joined Aventis Pharma Deutschland GmbH, where they served as Head of Drug Safety and Pharmacovigilance. In 2004, they joined Merck KGaA as VP of Corporate Drug Safety. Rainer then went on to work for Biotest AG as VP of Corporate Drug Safety and Pharmacovigilance.
Rainer Schmeidl earned their MD and PhD degrees in Medicine from Goethe University Frankfurt between 1975 and 1984.
This person is not in the org chart
This person is not in any offices
Biotest
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.